PALVELLA THERAPEUTICS, INC.
Develops therapies for serious, rare genetic skin diseases (genodermatoses).
PVLA | US
Overview
Corporate Details
- ISIN(s):
- US7207951036
- LEI:
- Country:
- United States of America
- Address:
- 353 W. LANCASTER AVENUE, 19087 WAYNE
- Website:
- https://palvellatx.com/
- Sector:
- Manufacturing
Description
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for serious, rare genetic skin diseases (genodermatoses). The company's lead product candidate is QTORIN rapamycin, a novel, patented 3.9% rapamycin anhydrous gel. As a mammalian target of rapamycin (mTOR) inhibitor, QTORIN is designed to address skin diseases driven by the overactivation of the mTOR pathway. The candidate is in clinical development for conditions including microcystic lymphatic malformations (Phase 3) and cutaneous venous malformations (Phase 2).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all PALVELLA THERAPEUTICS, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for PALVELLA THERAPEUTICS, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for PALVELLA THERAPEUTICS, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
